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Abstract
Cold atmospheric plasma (CAP) has been gaining increasing interest as a new approach
for the treatment of skin diseases or wounds. Although this approach has demonstrated
promising antibacterial activity, its exact mechanism of action remains unclear. This study
explored in vitro and in vivo whether CAP influences gene expression and molecular mech-
anisms in keratinocytes. Our results revealed that a 2 min CAP treatment using the Micro-
PlaSter ß in analogy to the performed clinical studies for wound treatment induces
expression of IL-8, TGF-ß1, and TGF-ß2. In vitro and in vivo assays indicated that keratino-
cyte proliferation, migration, and apoptotic mechanisms were not affected by the CAP treat-
ment under the applied conditions. Further, we observed that antimicrobial peptides of the
ß-defensin family are upregulated after CAP treatment. In summary, our results suggest
that a 2 min application of CAP induces gene expression of key regulators important for in-
flammation and wound healing without causing proliferation, migration or cell death in kera-
tinocytes. The induction of ß-defensins in keratinocytes describes an absolutely new
plasma strategy. Activation of antimicrobial peptides supports the well-known antibacterial
effect of CAP treatment, whereas the mechanism of ß-defensin activation by CAP is not in-
vestigated so far.
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Introduction
Plasmas have been used for a long time for sterilization of medical equipment or for sterile
packaging in the food industry [1–3]. In the last years, cold atmospheric plasma (CAP) sources
have been developed that provide the possibility to extend the plasma treatment to living tissue.
This opens up new horizons. CAP has the great potential for contact-free disinfection in sec-
onds and can access even microscopic openings and ragged surfaces. In contrast to antibiotic
or antiseptic treatments and according to present knowledge, allergic or toxic reactions are not
expected by the CAP treatment, however, the molecular effects on eukaryotic cells have been
insufficiently investigated up to now. Several in vivo and ex vivo studies with different plasma
devices approved a rapid reduction of the bacterial load or even of candida biofilms after the
CAP treatment [4–11].
Studies on the effects of CAP on mammalian cells have been also conducted by several re-
search groups. Summarizing the in vitro results demonstrated that CAP affects cells in a dos-
age- and device-dependent manner and can cause necrosis, apoptosis, or cell detachment [12–
16]. Besides the alteration of cell adhesion, exposure to CAP causes a temporary cell membrane
permeabilization [17] and inhibition of cell migration [18]. In addition, authors reported an in-
duction of cell proliferation after treatment with CAP. The observed stimulation of cell prolif-
eration presumably results from the release of growth factors (e.g. fibroblast growth factor-2
(FGF2)) by the plasma-treated cells but seems to be again cell- and plasma device specific [19].
Our own recently published data on fibroblasts revealed that a 2 min CAP treatment using the
MicroPlaSter ß has no influence on fibroblast proliferation, whereas fibroblast migration was
significantly induced [20].
Comparing the results from different groups working in the area of plasma medicine is
therefore not easy due to different plasma sources, treatment modalities and conditions.
All the more it is indispensable to understand the molecular basis behind the plasma
phenomenon.
Identification of target genes and molecular mechanisms which are affected by the CAP
treatment in keratinocytes is the basis of the present study. Understanding the mechanisms of
CAP-cell interactions is absolutely necessary and crucial to assure safety during CAP-disinfec-
tion or CAP-skin/wound treatment. Furthermore, the effect of CAP on cell culture studies with
normal keratinocytes have not been investigated so far, although keratinocytes of the epidermal
layer are the most directly affected cells during the CAP treatment of the skin. We chose the
MicroPlaSter ß for our experiments, since several published clinical studies on humans with e.
g. acute or chronic wounds already showed the beneficial effects of this specific plasma source
[5, 6, 21–23].
Materials and Methods
Plasma device and treatment of cells
The CAP device employed in this study was the MicroPlaSter ß plasma torch system (Micro-
wave 2.45 GHz, 80 W, argon flow 4.0 l/min, treatment diameter ~5cm) developed by the Max
Planck Institute for Extraterrestrial Physics in Garching/Germany and built by ADTEC Plasma
Technology Co. Ltd., Hiroshima/London. This device was also used in clinical studies for the
treatment of chronic and acute wounds [5] and for skin pruritus [23]. Treatment of keratino-
cytes with CAP was performed in analogy to our previous study with fibroblasts and described
in detail in our manuscript [20].
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Cell culture conditions
Primary human skin keratinocytes were purchased from Cascade Biologics (Eugene, OR, USA;
Lot: 5C0733) and ATCC (Manassas, VA, USA; Lot: 58732331 and Lot: 60245430) and were
cultured according to [24].
For the treatment of keratinocytes with cell culture supernatants, 100000 cells were seeded
into each well of a 12-well plate and incubated with 1 ml of supernatant obtained from kerati-
nocytes 24 h after cells were directly treated with CAP or control for 2 min. Supernatants were
collected from 3 individual experiments. Gene expression was analyzed 6 h, 24 h, 48 h, and 72
h after incubation was started.
Human Apoptosis Array
Human Apoptosis Arrays (array kit ARY009, R&D systems, Minneapolis, USA) were per-
formed according to the manufacturer´s instructions and allow a parallel determination of 35
apoptosis related proteins (Bad, Bax, Bcl-2, Bcl-x, Pro-Caspase-3, Cleaved Caspase-3, Catalase,
cIAP-1, cIAP-2, Clapsin, Clusterin, Cytochrome c, TRAIL R1/DR4, TRAIL R2/DR5, FADD,
Fas/TNFSF6, HIF-1 alpha, HO-1/HMOX1/HSP32, HO-2/HMOX2, HSP27, HSP60, HSP70,
HTRA2/Omi, Livin, PON2, p21/CIP/CDNK1A, p27/Kip1, phospho-p53 (S15), phospho-p53
(S46), phospho-p53 (S392), phospho-Rad17 (S635), SMAC/Diablo, Survivin, TNF RI/
TNFRSF1A, XIAP). Keratinocyte treatment, isolation of cellular extracts, and densitometry of
the array spots were performed according to [20].
Human Cytokine Array
Human Cytokine Arrays (array kit ARY005, R&D systems, Minneapolis, USA) were per-
formed according to [20] using cell supernatants, collected from keratinocytes 24 h after a 2
min CAP treatment or from untreated control cells and offer a parallel determination of 36 cy-
tokines, chemokines, and acute phase proteins (C5a, CD40 ligand, G-CSF, GM-CSF, CXCL1/
GRO alpha, CCL1/I-309, ICAM-1, IFN-gamma, IL-1 alpha, IL-1 beta, IL-1 ra, IL-2, IL-4, IL-5,
IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-16, IL-17, IL-17E, IL-23, IL-27, IL-32 alpha, CXCL10/IP-
10, CXCL11/I-TAC, CCL2/MCP-1, MIF, CCL3/MIP-1 alpha, CCL4/MIP-1 beta, CCL5/
RANTES, CXCL12/SDF-1, Serpin E1/PAI-1, TNF-alpha, TREM-1).
Enzyme-linked immunosorbent assay (ELISA)
Cell supernatants were collected 24 h, 48 h, and 72 h after a 2 min CAP treatment or of untreat-
ed control keratinocytes and were analyzed by ELISAs, respectively, according to [20]. ELISAs
for the detection of TGF-ß1 and TGF-ß2 were received from R&D Systems, Wiesbaden-Nor-
denstadt, Germany, and for the detection of human HBD-1, HBD-2, and HBD-3 were obtained
from US Biological, Salem, MA, USA. Each sample was assayed in duplicates, and the entire ex-
periments were performed three times.
FlowCytomix Simplex Technology
The Human FlowCytomix Simplex Detection System (eBioscience, San Diego, CA 92121,
USA) was used to quantify the protein amount of IL-8 from cell supernatants collected 24 h, 48
h, and 72 h after a 2 min CAP treatment or from untreated control keratinocytes according to
[20]. Each sample was assayed in duplicates, and the entire experiments were performed
three times.
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Analysis of mRNA expression by quantitative RT-PCR
Isolation of total cellular RNA from keratinocytes 6 h, 24 h, 48 h, and 72 h after the CAP treat-
ment and reverse transcriptase reaction was performed according to [20] and [25]. Quantita-
tive RT-PCR was performed with specific sets of primers and conditions (Table 1) applying
LightCycler technology (Roche Diagnostics, Mannheim, Germany) as described [25]. Each
RT-PCR was performed in duplicates with cDNA of at least three different keratinocyte
cell cultures.
Proliferation Assay (XTT)
XTT Proliferation Assay (Roche Diagnostics, Mannheim, Germany) with keratinocytes was
performed 24 h, 48 h and 72 h after CAP exposure for 2 min according to [20, 26]. Each sample
was assayed in duplicates, and the entire experiments were performed three times with three
different keratinocyte cell cultures.
Migration Assay
The migratory behaviour of CAP treated or control treated keratinocytes was assayed by
means of a wound healing assay. The migration rate into the “wound area” was documented
and measured 7 h and 12 h after the culture-insert was removed leaving a cell-free gap (“de-
fined wound”) as described in detail in [20].
Mouse experiments
For the experiments 129Sv/Ev female mice between 8 and 12 weeks of age were used. The mice
were anesthetized according to [20], and animals´ backs were shaved. Four mice became a
daily CAP treatment using the MicroPlaSter ß (80 W, argon flow 4 l/min) for 2 min, 5 days
Table 1. Primers and conditions.
Primer name Forward primer Reverse primer Condition(annealing,
melting)
human ß-actin 50-TACGTCGCCCTGGACTTCGAGC-30 50-GATGGAGCCGCCGATCCACACGG-30 ann. 62°C, mt 78°C
human IL-8 50-CTGCAGCTCTGTGTGAAGGTG-30 50-ACAGAGCTCTCTTCCATCAG-30 ann. 60°C, mt 81°C





ann. 65°C, mt 78°C
human BD-1 (HBD-1) 50-TTGTCTGAGATGGCCTCAGGTGGTAAC-
30
50-ATACTTCAAAAGCAATTTTCCTTTAT-30 ann. 60°C, mt 82°C
human BD-2 (HBD-2) 50- TCAGCCATGAGGGTCTTGTA-30 50-GGATCGCCTATACCACCAAA-30 ann. 60°C, mt 78°C
human BD-3 (HBD-3) 50-TTGCTCTTCCTGTTTTTGGTG-30 50-CGCCTCTGACTCTGCAATAA-30 ann. 60°C, mt 74°C
murine ß-actin 50-GTGGGCCGCTCTAGGCACCAA-30 50-CTCTTTGATGTCACGCACGATTTC-30 ann. 60°C, mt 86°C
murine TGF-ß1 (mTGF-
ß1)
50-GGCTCTGGAGAACAGCACATC-30 5´-CAAGCAGTCCTTCCCTTCAGG-30 ann. 60°C, mt 89°C
murine TGF-ß2 (mTGF-
ß2)
50-TGGCGCTCAGTCTGTCTACCT-30 5´-TTGGCGTAGTACTCCTCGTCG-30 ann. 60°C, mt 89°C
murine BD-1 (MBD-1) 50-CCAGATGGAGCCAGGTGTTG-30 50-TGGTATTAGATGGGCAGCTGG-30 ann. 65°C, mt 83°C
murine BD-2 (MBD-2) 50-GCTGCTGATATGCTGCCTCC-30 50-TGGCAGAAGGAGGACAAATGG-30 ann. 63°C, mt 75°C
murine BD-3 (MBD-3) 50-TTCTCCTGGTGCTGCTGTCTC-30 50-GAGTGTTGCCAATGCACCG-30 ann. 63°C, mt 82°C
Primer sequence is given from 5´➔ 3´ DNA strand. Ann: annealing temperature; mt: melting temperature.
doi:10.1371/journal.pone.0120041.t001
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long. Control mice were treated with the placebo modus of the MicroPlaSter ß for 2 min in-
stead of plasma, to resemble the same stress-situation for all animals. To circumvent any po-
tential indirect activation of the innate immune system, we performed an antiseptic treatment
with octenidine (Octenisept Schuelke & Mayr GmbH, Norderstedt, Germany) as described by
[7] prior to each CAP or placebo treatment using additionally four mice per group. All mice
were immediately sacrificed after therapy and the treated skin area was excised.
Preparation of epidermal RNA was performed according to [20] and mRNA expression was
analyzed by quantitative RT-PCR as described above. All animal experiments were conducted
with appropriate permission from the animal rights commission of the state of Bavaria and
maintained in agreement with the European Union guidelines. All experiments were approved
by the Committee on the Ethics of Animal Experiments of the University of Regensburg, Ger-
many (Permit Number: 54–2532.1–10/11).
Immunohistochemistry
Immunohistochemical staining was performed on 4-μm formalin-fixed, paraffin-embedded
skin sections. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide (Dako
Cytomation GmbH, Hamburg, Germany). Antigen retrieval was carried out in Tris-EDTA
buffer (1mM, pH 8.5) for 5 min at 120°C in a pressure cooker. Ki67 [SP6] antibody (abcam,
Cambridge, UK) at a dilution of 1:500 and murine ß-defensin-2 antibody (DEFB4
ABIN674574 from antibodies-online) at a dilution of 1:100 was applied for 30 min at room
temperature. Subsequent reactions were performed with the Histofine Simple Stain Mouse
MAX PO (rabbit) biotin-free horseradish peroxidase enzyme–labeled polymer detection sys-
tem. Positive reactions were visualized with diaminobenzidine (DAB) (Dako) followed by
counterstaining with hematoxylin (Merk, Darmstadt, Germany). Evaluation of the staining
was performed semi-quantitatively by means of light microscopy (Carl Zeiss Vision, Hallberg-
moos, Germany) in magnification as indicated.
TUNEL assay
TUNEL assay on paraffin sections was conducted for the detection of apoptotic cells in CAP
and placebo treated skin tissue according to [27] and was evaluated by fluorescence microscopy
(Axio Imager Z1; Zeiss).
Statistical analysis
Results are expressed as the mean ± SD. Comparisons between groups were made using Stu-
dent’s unpaired t-test. A p value< 0.05 was considered statistically significant (p< 0.05). All
calculations were performed using the GraphPad Prism software package (GraphPad Software
Inc., San Diego, CA, USA).
Results
The aim of this study was to explore whether the CAP treatment using the MicroPlaSter ß af-
fects gene expression and molecular mechanisms in differentiated skin keratinocytes in in vitro
and in vivo approaches.
CAP induces IL-8 expression in keratinocytes involved in inflammation,
fibrosis and wound healing
Cytokines are extracellular signaling molecules that mediate cell-cell communication. They are
released from cells and have critical roles in many biological processes such as immunity,
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inflammation, and fibrosis or wound healing. Amongst others, they regulate cellular growth,
differentiation, gene expression, migration or cell proliferation [28–30]. In most biological pro-
cesses, multiple cytokines operate in a large network, where the action of one cytokine is regu-
lated by the presence or absence of other cytokines [30, 31].
In our previous study, we observed that different cytokines and acute phase proteins e.g.
CD40 ligand, GRO alpha, IL-1ra, IL-6, IL-8, MCP-1, and Serpin E1 are positively affected by
the CAP treatment in fibroblasts [20]. Hence, we were interested whether the CAP treatment
targets the same molecules in keratinocytes or whether different cytokines are affected.
For analysis, keratinocytes were exposed to CAP for 2 min or remained untreated and
were further incubated for 24 h before supernatants were collected and processed for the si-
multaneous detection of the relative expression levels of 36 human cytokines and acute
phase proteins. Surprisingly, we observed that only interleukin 8 (IL-8) out of 36 analyzed cy-
tokines was significantly up-regulated by the CAP treatment for 2 min (fold change (CAP/
ctr.) 3.01; p value 0.0467). Array results concerning IL-8 induction were verified on mRNA
level at different time points (6 h, 24 h, 48 h, and 72 h) after the CAP treatment (Fig. 1a) and
Fig 1. Expression of IL-8, TGF-ß1, and TGF-ß2 after the CAP treatment. (a, b, c) mRNA expression analysis of IL-8, TGF-ß1, and TGF-ß2 in human
keratinocytes was performed 6 h, 24 h, 48 h, and 72 h after CAP treatment for 2 min by LightCycler 1.2 technology. (d, e, f) IL-8 secretion by human
keratinocytes was analyzed 24 h, 48 h, and 72 h after CAP treatment for 2 min by FlowCytomix and TGF-ß1, and TGF-ß2 secretion by ELISA Technology (g)
mRNA expression of murine TGF-ß1 (mTGF-ß1) and murine TGF-ß2 (mTGF-ß2) in epidermal skin was analyzed after 5x CAP treatment for 2 min and was
compared to corresponding placebo control. *p< 0.05.
doi:10.1371/journal.pone.0120041.g001
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on protein level determined by FlowCytomix Technology 24 h, 48 h, and 72 h after exposure
(Fig. 1d). FlowCytomix results confirmed a significant IL-8 induction 24 h after CAP treat-
ment. On mRNA level a significant induction was obtained after 48 h and 72 h, whereas a
non-significant induction was already seen 24 h after CAP treatment. A dual effect of
plasma could lead to a fast secretion of preformed IL-8 protein within 24 h on one hand and
also to a production of new IL-8 on the other hand, which could explain the later IL-8
mRNA levels.
CAP activates the expression of TGF-ß1 and TGF-ß2 in keratinocytes
TGF-ßs are the most studied molecules in wound healing and are well characterized in many
inflammatory or fibrotic diseases. They are produced by several cell types including activated
macrophages, fibroblasts, and keratinocytes and it is known that temporal activation of TGF-
ßs promotes wound healing [32]. In addition, several studies demonstrated the relevance of
TGF-ßs, since loss or over-expression are associated with wound healing defects or inflamma-
tory diseases [33–36].
Therefore, we were interested whether the expression of TGF-ßs is modulated by the CAP
treatment in keratinocytes. In analogy to our results obtained for fibroblasts [20], we observed
that TGF-ß1 and TGF-ß2 are likewise induced in keratinocytes. On mRNA level, we observed
a significant induction of TGF-ß1 24 h and 48 h after CAP treatment (Fig. 1b), whereas the in-
duction of TGF-ß1 on protein level was not significant at the indicated time points (Fig. 1e).
TGF-ß2 was significantly induced 24 h and 48 h after CAP treatment on mRNA level (Fig. 1c)
and 24 h after treatment on protein level (Fig. 1f). Furthermore, both TGF-ßs are significantly
up-regulated in the epidermal murine skin after 5x CAP treatments for 2 min compared to pla-
cebo control (Fig. 1g).
Apoptosis is not affected by the CAP treatment in keratinocytes in vitro
and in vivo
Different studies including our own study on malignant melanoma could show that apoptosis
is induced in tumor cells by CAP treatment using different CAP devices and treatment condi-
tions [37–39]. As described in the introduction part many studies observed apoptosis in nor-
mal cells after the CAP treatment [12–16, 40]. To ensure the safe usage of CAP on the skin,
treatment parameters and CAP devices must be adapted to exclude/reduce apoptotic effects on
normal cells. In our previous study we observed that the apoptotic machinery was not affected
by the CAP treatment in fibroblasts under current clinical treatment conditions (2 min treat-
ment using the MicroPlaSter ß) [20].
To analyze whether apoptosis is affected by CAP in keratinocytes, we used a human apopto-
sis array which detects 35 apoptosis-related proteins and searched for candidates differentially
expressed 24 h after CAP treatment for 2 min. In analogy to our result obtained for fibroblasts
[20] the evaluation of the array showed that these pro-apoptotic or anti-apoptotic factors were
not influenced by the CAP treatment in keratinocytes (S1 Table). Additionally, we analyzed
the skin of the treated mice for the appearance of apoptotic cells. Here, we observed that the
number of apoptotic cells in the treated skin area did not differ between 5x CAP or 5x placebo
treatment for 2 min (Fig. 2a, b). These results suggest that apoptotic mechanisms are not acti-
vated in keratinocytes by the CAP treatment under used treatment conditions.
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CAP treatment does not modulate keratinocyte proliferation and
migration in vitro and in vivo
Next to apoptosis, cell viability is an important marker to screen for cytotoxic effects of CAP
on eukaryotic cells. In order to determine the number of viable cells the XTT (2,3-Bis-(2-meth-
oxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt) assay was used.
Proliferation of keratinocytes in vitro was not significantly changed after CAP treatment for
2 min analyzed 24 h, 48 h, and 72 h after exposure (Fig. 3a). Ki67 staining of skin sections con-
firmed our in vitro results, showing that the proliferation of cells was limited to keratinocytes
of the basal layer of the epidermis (I) and the bulge region of the outer root sheath of the hair
follicle (II) and did not differ between CAP and placebo control after 5x exposure for 2 min
(Fig. 3b). Furthermore, we wanted to know whether migration is affected by the CAP treatment
in keratinocytes because in our previous study we could show that a 30 sec treatment with CAP
Fig 2. Detection of apoptotic cells in CAP and placebo treatedmurine skin tissue. Apoptotic cells were analyzed using a fluorometric TUNEL assay
system for detection of fragmented DNA as indicator of apoptotic events. Representative photomicrographs are presented of placebo and CAP treated skin.
Arrowheads exemplarily indicate apoptotic cells. Number of TUNEL positive cells were counted in three different fields and averaged. Placebo treatment was
set to 100% ± SD. Magnification as indicated.
doi:10.1371/journal.pone.0120041.g002
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significantly activates fibroblast migration [20]. The treatment time for this assay has to be re-
duced because it is known that CAP treatment temporarily results in a detachment of the cells
and inferential leads to a delayed migration ability [18]. In contrast to our results obtained for
fibroblasts [20], we observed that migration was not significantly modified in keratinocytes
treated with CAP for 30 sec (Fig. 3c, d).
CAP promotes the expression of ß-defensins in keratinocytes
Based on the fact that CAP activates the pro-inflammatory cytokine IL-8 and the immunoreac-
tive TGF-ß1 and TGF-ß2 in keratinocytes, we suggest that other inflammation-related mole-
cules might be affected by CAP.
Fig 3. CAP effects on keratinocyte proliferation andmigration. (a) Cell proliferation was determined using a XTT proliferation assay 24 h, 48 h and 72 h
after the CAP exposure for 2 min and compared to control (ctr.). (b) Representative examples of immunohistochemical stains of formalin-fixed paraffin-
embedded skin sections using Ki67, a proliferation marker that stains the nuclei of cells in G1, S, G2 and early mitosis. Highly proliferative, Ki67-positive
keratinocytes were observed within the basal layer of the epidermis (I) and the bulge region of the hair follicle (II), whereas no difference between 5x placebo
or 5x CAP treatment for 2 min was observed. Magnification as indicated. (c, d) Cell migration was determined using a wound healing assay. The migration
rate was calculated 7 h and 12 h after culture insert was removed and displayed as the percentage relative to untreated control (ctr. set 100%).
Representative images are shown immediately after culture insert was removed (0 h) and 7 h and 12 h later.
doi:10.1371/journal.pone.0120041.g003
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Further important inflammation-related molecules are the defensins. Defensins are small
cysteine-rich cationic proteins and function as antimicrobial peptides (AMPs) [41, 42]. They
are active against bacteria, fungi and many viruses. Cells of the immune system and almost all
epithelial cells express these peptides to assist in killing phagocytosed bacteria. Most defensins
function by binding to the microbial cell membrane, and, once embedded, forming pore-like
membrane defects that allow efflux of essential ions and nutrients. Defensins are found in the
human skin during inflammatory conditions like atopic dermatitis and also during wound
healing [42, 43]. Since CAP is highly effective against bacteria we assumed that activation of an-
timicrobial peptides might contribute to the antiseptic efficacy of CAP observed in vivo.
We analyzed the expression of human ß-defensin, HBD-1, HBD-2, and HBD-3, and ob-
served that HBD-2 is significantly induced 6 h and 24 h after the CAP treatment for 2 min
(Fig. 4b), whereas HBD-1 and HBD-3 mRNA expression was induced but not significantly by
the CAP treatment (Fig. 4a, 4c). A significant induction of HBD-2 was also obtained on protein
level 24 h after CAP treatment (Fig. 4e). The protein amount of HBD-1 was not significantly
modified after CAP treatment for 2 min (Fig. 4d) and the sensitivity of the BD-3 ELISA was
not sufficient to detect HBD-3 protein in the supernatant of both CAP and control treated ker-
atinocytes (data no shown). These results let us speculate that under used treatment conditions
HBD-2 is the most important human ß-defensin affected by the CAP treatment. Furthermore,
also murine ß-defensins were analyzed in the epidermal skin after 5x CAP treatment for 2 min
on mRNA level (Fig. 4f). MBD-2 and MBD-3 were significantly induced after the CAP treat-
ment, whereas MBD-1 was not significantly induced. Immunohistochemistry confirmed an in-
creased expression of murine MBD-2 in epidermal cells after the CAP treatment (Fig. 4g,
arrowhead).
These data suggest that CAP promotes the expression of ß-defensins in human and murine
keratinocytes and might contribute to the well-known antibacterial effects of the
CAP treatment.
CAP is able to directly activate gene expression in keratinocytes
Next, we wanted to distinguish whether CAP is able to directly affect gene expression in kerati-
nocytes or whether the induction of genes is a result of a potential indirect activation of the in-
nate immune system. In an in vitro approach, we incubated keratinocytes with cell culture
supernatants obtained from keratinocytes directly treated with CAP for 2 min or from kerati-
nocytes which remained untreated (ctr. supernatant) (S1 Fig.). The expression of IL-8, TGF-
ß1, TGF-ß2, HBD-1, and HBD-2 in keratinocytes exposed to supernatants of CAP-treated ker-
atinocytes was not significantly modified, suggesting that CAP primarily affects these genes di-
rectly. Interestingly, HBD-2 was significantly induced 72 h after keratinocytes had been
exposed to CAP supernatants. Here, we cannot exclude any kind of indirect CAP induction.
In an in vivo approach, we tried to circumvent any potential indirect activation of the innate
immune system by using an antiseptic treatment prior to the use of CAP or placebo treatment.
A non-significant induction of TGF-ß1 and a significant induction of TGF-ß2 were obtained
in the murine epidermal skin when we performed an antiseptic treatment with Octenisept
prior to the CAP treatment (S2a Fig.). Furthermore, also MBD-1 and MBD-3 were significantly
induced under these treatment conditions (S2b Fig.), suggesting that CAP is able to directly ac-
tivate gene expression in keratinocytes.
Discussion
Over the past few years, plasma medicine has become an important field in medical science.
Cold atmospheric plasma (CAP) has proven anti-inflammatory, anti-microbial and anti-
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Fig 4. Human andmurine ß-defensin expression after the CAP treatment. (a, b, c) mRNA expression of human ß-defensin-1 (HBD-1), ß-defensin-2
(HBD-2), and-3 (HBD-3) was analyzed 6 h, 24 h, 48 h, and 72 h in keratinocytes after the CAP treatment for 2 min. (d, e) ELISAs present the relative level of
human BD-1 (HBD-1) and human BD-2 (HBD-2) secretion by keratinocytes after the CAP treatment for 2 min compared to control (ctr.). (f) mRNA expression
of murine ß-defensins, MBD-1, MBD-2, and MBD-3 in epidermal skin tissue after 5x CAP treatment for 2 min compared to placebo control. *p< 0.05. (g)
Immunohistochemistry against murine BD-2 (MBD-2) in murine tissue after 5x CAP treatment versus placebo control. Arrowheads exemplarily indicate MBD-
2 positive keratinocytes, whereas a more intensive staining was observed in the CAP treated skin.
doi:10.1371/journal.pone.0120041.g004
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neoplastic effects and promotes wound healing [5, 44, 45]. Before implementing plasma as new
medical treatment tool, effects and safety on eukaryotic cells must be proven.
In the present study we aimed to define differentially regulated genes and molecular mecha-
nisms, which are affected by the CAP treatment. Keratinocytes are in focus of the present
work, because these cells are primarily affected by skin disinfection or skin/wound treatments
and concerning plasma effects they are not sufficiently analyzed so far.
Interestingly, we observed that analyzed cytokines and acute phase proteins, crucial for in-
flammation, fibrosis or wound healing, were practically not affected by CAP in keratinocytes
under used treatment conditions (2 min treatment using the MicroPlaSter ß). Only the pro-in-
flammatory cytokine IL-8 was significantly up-regulated in vitro. IL-8 can be induced directly
or indirectly by the CAP treatment. It might be possible that after CAP treatment of 2 min sin-
gle cells are damaged or are temporarily detached from the cell culture dish and are able to in-
duce parts of the innate immune system of surrounding keratinocytes in an autocrine mode.
At the other hand it is known from the literature that IL-8 is constitutively expressed in normal
cultured keratinocytes and increases rapidly after UVB irradiation [46], which is also directly
discharged by CAP. To analyze, whether CAP affects keratinocytes directly or indirectly, we in-
cubated keratinocytes with supernatants obtained from CAP-treated keratinocytes. Interesting-
ly, we observed no significant induction of IL-8, TGF-ß1, TGF-ß2, HBD-1, and HBD-3 (S1
Fig.), suggesting that CAP predominantly affects gene expression in these cells directly. The
significant induction of HBD-2 observed 72 h after incubation with CAP-treated supernatants
indicates that indirect CAP effects may also exist.
Since CAP is able to kill bacteria, it would be possible that this antimicrobial mechanism
can indirectly affect the induction of these genes. To analyze this we performed an antiseptic
treatment prior the use of CAP or placebo treatment in our mouse model to exclude antimicro-
bial influences. The significant induction of murine TGF-ß2, MBD-1, and MBD-3 on mRNA
level (S2 Fig.) support that CAP directly affects gene expression in keratinocytes. Interestingly,
the induction intensity of all analyzed genes was lower using an antiseptic treatment prior to
each CAP treatment in comparison to the CAP treatment alone (Fig. 1g and Fig. 4f), suggesting
that antimicrobial influences may also exist, which must be investigated in future research. Ad-
ditionally, paracrine mechanisms must be also considered in vivo. A possibility why nearly no
cytokine, chemokine, and acute phase protein is regulated by the CAP treatment in keratino-
cytes might be the absence of paracrine mechanisms in our in vitro approaches. During wound
healing we observed that CAP induces different cytokines in fibroblasts in vitro as well as in
vivo [20], whereas these molecules are not affected in keratinocytes. We believe that the inter-
play between fibroblasts and keratinocytes is required to provoke cellular mechanisms impor-
tant for e.g. wound healing.
Remarkable, however, is the activation of TGF-ßs after CAP treatment. Our results from
this work and our previous study [20] revealed that TGF-ß1 and TGF-ß2 are induced in kerati-
nocytes as well as in fibroblasts after the CAP treatment. It is known that TGF-ß can both act
on and be secreted by diverse cell types which participate in the wound healing process. Ac-
tions of TGF-ß to stimulate chemotaxis, fibrogenesis, angiogenesis, and autoinduction of its ex-
pression have shown to improve healing in a variety of animal models of both normal and
impaired wound healing [47].
In our study we observed that apoptosis is not provoked by CAP under used conditions.
Furthermore, we observed that cell viability (analyzed by XTT proliferation assay) in vitro and
cell proliferation (analyzed by Ki67 immunohistochemical staining) in vivo was also not modi-
fied under applied conditions in keratinocytes. These results are desirable and fulfill basic rec-
ommendations for the safe use of the MicroPlaSter ß on the skin. Important to note is that we
observed an accelerated re-epithelialization (due to an increased keratinocyte proliferation)
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after CAP treatment in an animal wound healing model [20]. We suggest that the CAP discrep-
ancy concerning cell proliferation depends on the property of the skin and varies between
healthy and wounded skin. Regrettably, the complex mechanism and the molecular changes
which may elucidate the present phenomenon are not investigated so far.
To ensure the safe usage of CAP on the skin (e.g., for skin disinfection, for wound treatment
or treatment of skin diseases) further studies concerning mutagenicity and cancerogenicity
must be performed. Own unpublished data and results from Boxhammer and colleagues [48]
suggest that mutagenicity is presumably not inducible in eukaryotic cells under used treatment
conditions, whereas further studies using different cell types, plasma devices, and treatment
conditions must approve this suggestion.
Several studies revealed that plasma exhibits strong antimicrobial efficacy in vitro and in
vivo by directly killing bacteria [4, 6–9, 49]. Our present study describes an absolutely new plas-
ma strategy in order to reduce the bacterial load: the activation of defensins in keratinocytes.
Defensins are host-defense peptides produced by eukaryotic cells which perform antimicrobial
functions to combat infection during wound healing (Gibson et al., 2012) or other skin diseases
[43, 50, 51]. We observed that different human and murine ß-defensins are inducible by the
CAP treatment in keratinocytes. Future studies must clarify how CAP exactly activates ß-
defensins in keratinocytes because induction of host defense peptides is an important mecha-
nism requested for skin disinfection or chronic wound treatment.
In summary, this study provides evidence that a short application of CAP using the Micro-
PlaSter ß does not cause apoptosis and has no impact on keratinocyte migration and prolifera-
tion in vitro or on healthy skin. Furthermore, we observed that CAP activates human and
murine antimicrobial peptides in keratinocytes, which support the well-known antibacterial ef-
fects of CAP treatment.
Supporting Information
S1 Fig. Effect on gene expression after indirect CAP treatment in vitro. (a-f) mRNA expres-
sion of human IL-8, TGF-ß1, TGF-ß2, HBD-1, HBD-2, and HBD-3 in keratinocytes treated
with supernatants obtained from keratinocytes directly affected by CAP or control treatment
for 2 min. The supernatants were obtained 24 h after exposure and remained on the cells as in-
dicated (6 h, 24 h, 48 h, 72 h). p< 0.05.
(TIF)
S2 Fig. Effect on gene expression after an antiseptic treatment prior to the CAP treatment
in vivo. Expression of (a) murine TGF-ßs (mTGF-ß1 and mTGF-ß2) and (b) murine ß-defen-
sins (MBD-1, MBD-2, and MBD-3) in epidermal skin after a standard antiseptic Octenisept
treatment prior to a 2 min CAP or placebo treatment, 5 days long. p< 0.05.
(TIF)
S1 Table. Protein Array results. Fold change (CAP/control) and p value of analyzed molecules
from Human Apoptosis Antibody Array (R&D Systems,Inc.). p<0.05; ns: not significant.
(TIF)
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